Investors propelled shares of Cara Therapeutics Inc. (NASDAQ:CARA) to a one-year high Thursday after the company reported top-line results from the phase II trial of lead kappa opioid agonist CR845, which hit its primary endpoint in treating moderate to severe uremic pruritus (UP).